Zor Pharmaceuticals

Virulizen is an experimental oncology product that has demonstrated compelling efficacy as well as superior safety in pancreatic cancer patients. The drug has completed a phase III trial in pancreatic cancer, enjoys strong patent protection, and a large market potential in a variety of different cancers.

Zoticon finds highly significant data buried in failed phase III trial. Zoticon licenses product, hires top tiered management, authors patent and raises $8MM for confirmatory trial based on this data.